Haemoctin Sdh

Haemoctin Sdh is a prescription intravenous medication whose active ingredient is human coagulation factor VIII. It is supplied in a sterile solution intended for infusion and is used to replace deficient factor VIII in patients with hemophilia A. The product conforms to EU standards and is classified as a coagulation factor (ATC code B02BD02). It is administered under medical supervision and requires individualized dosing based on factor activity levels.

Haemoctin Sdh is indicated for the management of bleeding episodes and perioperative prophylaxis in individuals with hemophilia A.

- Treatment of acute bleeding episodes in hemophilia A patients. - Surgical or dental procedure prophylaxis to prevent excessive bleeding. - Routine prophylactic therapy to maintain factor VIII activity levels and reduce spontaneous joint bleeds. - On-demand replacement therapy when factor VIII levels fall below therapeutic thresholds. - Management of chronic hemophilia A in patients with inhibitors when used in combination with bypassing agents. - Support for patients undergoing major orthopedic surgery to achieve hemostasis.

The safety profile of Haemoctin Sdh includes both frequently observed and less common adverse reactions.

Common: - Mild fever or chills during infusion. - Headache or fatigue. - Local infusion site reactions such as erythema or swelling. - Nausea or mild abdominal discomfort. - Transient increase in liver enzymes. - Mild arthralgia. - Mild rash or urticaria. - Transient hypertension during infusion. - Transient tachycardia. - Mild dizziness.

Serious: - Development of inhibitors (antibodies) against factor VIII, reducing treatment efficacy. - Severe allergic reactions including anaphylaxis, bronchospasm, or angioedema. - Thrombotic events such as deep vein thrombosis or pulmonary embolism (rare). - Disseminated intravascular coagulation (very rare). - Renal dysfunction (rare). - Severe hemolysis (extremely rare). - Immune complex-mediated vasculitis (very rare).

Precautions for Haemoctin Sdh focus on patient assessment, monitoring, and risk mitigation before and during therapy.

- Verify diagnosis of hemophilia A and baseline factor VIII activity. - Screen for history of inhibitors or previous allergic reactions to factor VIII products. - Assess liver and renal function prior to initiation. - Monitor for signs of inhibitor development during treatment. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Ensure appropriate infusion rate to reduce infusion-related reactions. - Educate patients on recognizing symptoms of severe allergic reactions.

Haemoctin Sdh may interact with other medications that affect hemostasis, immune response, or infusion safety.

Avoid: - Concurrent use of other factor VIII concentrates without medical supervision. - Administration of bypassing agents in patients with known inhibitors unless specifically indicated. - Use of high‑dose vitamin K antagonists that may alter coagulation balance.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) may enhance clot stability and should be coordinated. - Immunosuppressive drugs can affect inhibitor development and require monitoring. - Concomitant use of drugs that cause hypertension (e.g., vasopressors) may increase risk of infusion reactions. - Live vaccines should be avoided during active treatment due to potential immune modulation.